Neutrophil extracellular traps (NETs) are web-like structures designed to trap and eliminate microbes. However, excessive NETosis can cause serious health issues, including sepsis, viral infections, autoimmune diseases, impaired diabetic wound healing, and cancer progression.
Elevated CitH3 levels are a key biomarker associated with these conditions, linked to immune dysfunction and tissue injury.
We have developed a humanized anti-CitH3 antibody (hCitH3-mAb) with superior binding capabilities compared to existing antibodies.
Partnering with a CDMO, we have scaled up hCitH3-mAb production in a GMP facility, achieving over 4.5 g/L yield with 99.5% purity. Proof-of-concept studies show hCitH3-mAb enhances survival in animal models of septic shock and viral infections, reduces cytokine storms, and accelerates wound healing in diabetic mice.
HTIC, Inc. seeks a $10-15 million investment for FDA IND filing and experienced leadership to drive commercialization. We welcome partnerships with large pharmaceutical companies to address urgent medical needs related to immune dysregulation and diabetic foot ulcers (DFU).